News May 22, 2025
Porton Advanced Announces Collaboration with TongEYE to Accelerate Development of iPSC-RPEC Transplantation Therapy
Suzhou, China, May 15, 2025 - Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with TongEye Medical Technology (TongEYE)，an innovator focusing on cell therapy drugs for ophthalmic diseases.
News May 22, 2025
Porton Advanced Announces Collaboration with Hualong Biological to Accelerate MATC Cell Therapy Development for Solid Tumor Treatment Breakthroughs
Suzhou, China, May 12, 2025 –Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Hualong Biological，an innovator in novel cancer therapeutics.
News May 16, 2025
Join Us at Chemspec Europe 2025 in June
As a benchmark exhibition in Europe, Chemspec Europe 2025 focuses on customized chemical solutions and innovative technologies. With its highly specialized positioning, the exhibition has become a core platform for global industry elites to connect resources and expand business networks. The exhibition, which covers the entire industry chain of pharmaceuticals, electronic chemicals, agricultural chemicals and other fields, is not only a hub for technology and knowledge exchange, but also an efficient channel for companies to explore the international market.
NewslettersMay 02, 2025
Porton Newsletter - April 2025 Recap
Technical Enabling Services & Solutions Company Events Marketing Activities
News Apr 16, 2025
Porton Advanced's End-to-End CDMO Solutions Accelerates IND Approval of Tasly's Innovative Dual-Targeting CAR-T Therapy
April 12, 2025 - Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD’s Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM).
NewslettersApr 11, 2025
Porton Newsletter - Q1 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities
NewslettersApr 11, 2025
Porton Newsletter - March 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities
News Mar 21, 2025
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News Mar 19, 2025
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
